Schizophrenia News

Among individuals at clinical high risk for psychosis, those with brief limited intermittent psychotic symptoms had higher risk for psychosis than those with attenuated psychotic symptoms. Researchers suggest clinical high-risk guidelines be updated to reflect these differences.

As the year comes to a close, Healio.com/Psychiatry revisited our most popular psychiatry coverage of 2015.

Among individuals with schizophrenia, exposure to benzodiazepines was associated with higher mortality, while exposure to antidepressants and antipsychotics was associated with lower mortality.

The FDA has accepted an investigational drug application for MIN-101, a 5-HT2a and sigma2 antagonist from Minerva Neurosciences, for treatment of schizophrenia, according to a company press release.

Recent findings identified three biomarker-based categories that outperformed traditional diagnoses in categorizing individuals with psychosis into distinct subgroups based on brain biology.

There has been an abundance of recently published studies exploring schizophrenia treatments and risk factors, comorbidities and interventions.

Impaired community functioning in schizophrenia followed different developmental trajectories; however, researchers found that impairments in social activity and functioning in school or work were familial.

The recent acquisition of Naurex by Allergan has provided the company with the opportunity to deepen its commitment to the mental health field.

Mylan recently announced the launch of clozapine orally disintegrating tablets, the generic version of Jazz Pharmaceuticals’ FazaClo, according to a company press release.

Independent genetic pathways lead to gray and white matter abnormalities in schizophrenia, suggesting white matter integrity as a potential primary phenotype linking genes to biological pathways associated with risk for schizophrenia.